GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sprint Bioscience AB (OSTO:SPRINT) » Definitions » Debt-to-Revenue

Sprint Bioscience AB (OSTO:SPRINT) Debt-to-Revenue : 0.00 (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sprint Bioscience AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Sprint Bioscience AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Sprint Bioscience AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Sprint Bioscience AB's annualized Revenue for the quarter that ended in Jun. 2024 was kr66.80 Mil. Sprint Bioscience AB's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.00.


Sprint Bioscience AB Debt-to-Revenue Historical Data

The historical data trend for Sprint Bioscience AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sprint Bioscience AB Debt-to-Revenue Chart

Sprint Bioscience AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.59 - N/A -

Sprint Bioscience AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sprint Bioscience AB's Debt-to-Revenue

For the Biotechnology subindustry, Sprint Bioscience AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's Debt-to-Revenue falls into.



Sprint Bioscience AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Sprint Bioscience AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 50.485
=0.00

Sprint Bioscience AB's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 66.796
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2024) Revenue data.


Sprint Bioscience AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sprint Bioscience AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sprint Bioscience AB Business Description

Traded in Other Exchanges
Address
Halsovagen 7, Floor 8, Elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a Sweden based company involved in developing drugs focused on cancer and metabolism. The project portfolio of the company includes STK25, VPS34, and PIP4K2.

Sprint Bioscience AB Headlines

No Headlines